A Deep Look at Globus Medical’s Financial Performance
In 3Q17, Globus Medical (GMED) generated sales of $151.7 million compared to $135.6 million in 3Q16.
Taking Stock of Globus Medical’s Recent Acquisitions
Most of Globus Medical’s revenue comes from the United States, and the rest comes from its international segment. In 3Q17, the United States contributed $125.9 million.
Analyst Ratings for Globus Medical and Its Peers in February
Of the 13 analysts covering Globus Medical in February 2018, seven of them have given the stock a “buy” or higher rating. Five analysts have given it a “hold.”
Behind MiMedx Group’s Recent Financial Performance
In 3Q17, MiMedx Group’s (MDXG) net sales rose to $84.6 million, compared with $64.4 million in 3Q16—a 31% YoY (year-over-year) rise.
Why the Physician Office Pain Management Market Matters to MiMedx
Through MiMedx’s donor program, a mother scheduled to deliver a baby by C-section can donate her placental tissue rather than leave it as medical waste.
Which Markets Is MiMedx Group Actually Targeting?
MiMedx estimates that the domestic skin and dermal substitute market will reach sales of $1.1 billion in 2020.
Understanding MiMedx Group’s Zealous Focus on Sales
MiMedx focuses on marketing efforts to increase revenues. The company has at its disposal a sales force of 320 professionals.
MiMedx Group on the Street: Analyst Recommendations in January
Of the four analysts covering MiMedx Group in January 2018, three have given the stock a “buy” rating, and one analyst has given it a “strong buy” rating.
Trial Progression of St. Jude Medical’s Stroke Prevention Device
On September 1, St. Jude Medical (STJ) launched its AMPLATZER Amulet IDE trial that will expand the device’s access to atrial fibrillation patients.